Flibanserin has 36 known drug interactions based on U.S. FDA drug labeling data. Of these, 21 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Amprenavir, Atazanavir, Boceprevir. Patients taking Flibanserin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 36
- Contraindicated
- 21
- Major
- 1
- Moderate
- 14
Contraindicated (21)
- Flibanserin + Amprenavir— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Atazanavir— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Boceprevir— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Ciprofloxacin— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Clarithromycin— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Conivaptan— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Diltiazem— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Erythromycin— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Fluconazole— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Fosamprenavir— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Indinavir— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Itraconazole— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Ketoconazole— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Nefazodone— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Nelfinavir— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Posaconazole— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Ritonavir— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Saquinavir— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Telaprevir— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Telithromycin— Strong CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
- Flibanserin + Verapamil— Moderate CYP3A4 inhibitor; concomitant use is contraindicated due to increased risk of hypotension and syncope.
Major (1)
- Flibanserin + Alcohol— Coadministration increases risk of hypotension, syncope, and CNS depression compared to ADDYI alone or alcohol alone.
Moderate (14)
- Flibanserin + Carbamazepine— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Flibanserin + Cimetidine— Weak CYP3A4 inhibitor; concomitant use of multiple weak inhibitors may increase risk of adverse reactions.
- Flibanserin + Diphenhydramine— Concomitant use may increase risk of CNS depression including somnolence.
- Flibanserin + Fluoxetine— Weak CYP3A4 inhibitor; concomitant use of multiple weak inhibitors may increase risk of adverse reactions.
- Flibanserin + Ginkgo— Weak CYP3A4 inhibitor; concomitant use of multiple weak inhibitors may increase risk of adverse reactions.
- Flibanserin + Nitrazepam— Concomitant use may increase risk of CNS depression including somnolence.
- Flibanserin + Oral Contraceptives— Weak CYP3A4 inhibitor; concomitant use of multiple weak inhibitors may increase risk of adverse reactions.
- Flibanserin + Phenobarbital— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Flibanserin + Phenytoin— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Flibanserin + Ranitidine— Weak CYP3A4 inhibitor; concomitant use of multiple weak inhibitors may increase risk of adverse reactions.
- Flibanserin + Rifabutin— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Flibanserin + Rifampin— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Flibanserin + Rifapentine— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.
- Flibanserin + St. John'S Wort— CYP3A4 inducer; concomitant use may decrease flibanserin exposure and therapeutic effect.